[Importance and limitations of the immunological monitoring of patients with malignant tumors].
The authors, after considering the incidence of neoplastic diseases is particularly high in subjects suffering from congenital or acquired immunologic lacks, assert the importance to perform an immunologic monitoring in the patients bearing malignant neoplasms, with the purpose to identify and calculate the direrent deficits of the sheltering organism. Then, they state the method adopted for the study of the cellulo-mediate immunity (in vivo and in vitro) and the humoral one. At last, on the basis of the results they obtained, the Authors, as a conclusion, affirm there is always in neoplastic patients a certain degree of depression of tumour immunity (especially if cellulo-mediate), and it can be put in relation to the evolutive stage of neoplasm.
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D003176:Complement C3 / Q000276:immunology; D003181:Complement C4 / Q000276:immunology; D004137:Dinitrochlorobenzene; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology; D014374:Tuberculin Test
D003176:Complement C3; D003181:Complement C4; D004137:Dinitrochlorobenzene; D007136:Immunoglobulins
Importanza e limiti del monitoraggio immunologico nei pazienti affetti da tumori maligni.